Fenwick Represents Day One Biopharmaceuticals in $130 Million Series B Financing

Fenwick represented Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating targeted cancer therapies for children and adults, in its $130 million Series B Financing.

The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

More information about the deal can be found through the company’s announcement.

The Fenwick transaction team was led by corporate partners Effie Toshav, Ryan Slunaker and included associates Eugene Karlik and Myles Gutenkunst, and tax partner Will Skinner and associate Timmoney Ng.